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al-Microglobulin (cx1-m) is a highly glycosylated polypeptide
of 182 amino acids associated with a brown chromophore
(Ekstr6m et al., 1975; Lopez Otin et al., 1984). The molecule
is heterogeneous in charge and was described as HC protein
(Tejler & Grubb, 1976) or acl-microglycoprotein (Seon &
Pressmann, 1978). It occurs in biological fluids as a 31 kDa
monomer and as a 90kDa component covalently associated
to one a chain of monomeric immunoglobulin A (IgA)
(Grubb et al., 1983; Vincent et al., 1985). The al-m gene is
associated with a gene coding for the HI-30 domain of inter-
ax-trypsin inhibitor, one of the acute phase proteins (Kau-
meyer et al., 1986). The human 31 kDa al-m was shown to
be synthesised by fetal liver explants (Tejler et al., 1978) and
we recently reported that the molecule was produced in vitro
by several human hepatoma cell lines but not by lymphoma
or plasmocytoma cell lines (Vincent et al., 1987). For these
reasons we have determined serum levels of al-m in a large
series of patients suffering from primary hepatocellular carci-
noma in order to evaluate the possible use of this molecule
as an additional tumour marker. The data show that 31 kDa
al-m levels are usually not increased in this disease, whereas
the 90kDa component levels are elevated in some cases.
Our study involved a hundred South African Blacks with
histologically proven hepatocellular carcinoma. They
included 11 women and 89 men whose ages ranged from 20
to 73 years (median 39). Seventy-seven healthy South
African Black subjects served as controls. All serum samples
were sent frozen in dry ice from South Africa and were
stored at -40°C until use.
The differential quantitation of 31 kDa and IgA-associated
90kDa ocl-m in unfractionated sera was performed by
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enzyme linked immunosorbent assay (ELISA) as previously
described (Vincent & Revillard, 1985). Briefly, the monoclo-
nal antibody 832 ALB which binds both forms of cxl-m with
high affinity (1.4 x1010 L/M) was used as solid phase. The
binding of serum a1-m was assessed by addition of polyconal
immunopurified biotinylated antibodies specific for cal-m or
for the heavy chain of IgA, then by incubation with
peroxidase-streptavidin, addition of the substrate and record-
ing of the absorbance at 280nm. Interassay coefficients of
variation did not exceed 16%. Normal levels of 31 kDa in 25
French adults were 9.54+2.73mg1 -1 (mean+s.d.). As
regards 90kDa al-m, normal levels in the same control
group were 101.9+36.6kU1 1 (Vincent & Revillard, 1987).
Albumin concentrations were measured by radial immuno-
diffusion, #2-microglobulin and IgA by competitive ELISA
(Vincent & Revillard, 1986; Vincent et al., 1985). ax-
Fetoprotein and HBs antigen were determined by solid phase
radio-immunoassay, y-glutamyl transpeptidase and alkaline
phosphatase activities by routine biochemical methods. The
upper limit values for serum 31 kDa and 90kDa o1-m were
defined by the 90th percentile of the control group (Soleberg,
1985). Comparisons between groups were based on the
Mann-Whitney U test.
Individual serum levels of 31kDa and 90kDa cx1-m are
presented in Figure 1. In healthy subjects from South Africa
serum levels of 31kDa cx1-m were similar to that of Euro-
pean controls whereas those of the 90kDa form appeared to
be slightly lower. Twenty-two patients had 31 kDa cl-m
levels above the upper limit of control values but the
distribution in patients did not differ from that of controls.
As regards 90kDa ox1-m levels, 35 patients had elevated
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Figure 1 Serum levels of 31 kDa cIl-m (a) and IgA-associated 90kDa pI-m (b) in 100 patients with hepatocellular carcinoma (H)
and 77 controls (C). The dashed lines indicate the median of the distribution in each group.
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values and the overall distribution differed from that of
healthy controls (P<0.002, Mann-Whitney U test). Serum
IgA concentrations were elevated in four of the patients and
were not correlated with 90kDa o 1-m levels. No difference in
c 1-m levels was found between the 54HBs antigen-positive
and HBs antigen-negative patients. The concentrations of
serum albumin were not correlated with those of (xi-m.
Finally, oa-fetoprotein was increased in 91% of patients' sera,
f2-microglobulin in 59%, alkaline phosphatase activity in
78% and y-glutamyltranspeptidase in 94% but none of these
biological parameters was correlated with a1-m levels.
Serum levels of 31 kDa a1-m were reported to rise in renal
insufficiency (Itoh et al., 1983; Yu et al., 1983) and in a few
patients with malignant tumours, including the only two
cases of hepatoma that were investigated (Tagaki et al.,
1980). Immunohistochemical studies of normal human
tissues showed that hepatocytes were intensely stained by
anti-cx1-m antibodies along with macrophages and some
lymphocytes (Bouic et al., 1984). Studies of human fetal
livers revealed that fetal hepatocytes but not haematopoietic
stem cells were strongly labelled by anti-a,-m antibodies
(Bouic et al., unpublished data). Furthermore, the protein
was shown to be synthesised by human fetal liver explants
(Tejler et al., 1978) and produced in high amounts by some
human hepatocarcinoma cell lines (Vincent et al., 1987).
Therefore al1-m was considered as a potential biologic
marker of hepatocellular carcinoma. However, the present
study demonstrates that this prediction was not confirmed,
despite the significant elevation of 90kDa a1-m in the
patients group as compared with controls.
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